Gleevec (Imatinib Mesylate) is the first choice breakpoint cluster region (BCR)/ABL targeted oral therapy that produced a complete response almost in 71% to 80% of patients affected with CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.